Hepartex — Company Profile

Hepartex 141, bureaux de la Colline 92213 Saint-Cloud France Tel.: +33 (0)1 46 02 13 15 Fax: +33 (0)1 46 02 48 66 Email: hepartex@hepartex.com Website: http://www.hepartex.com/

A unique global service from bulk Active Pharmaceutical Ingredients through to Marketing Authorisations and Finished Dosage Forms in synergy with our sister-company Venipharm.

Company profile

Since 1977 HEPARTEX has been marketing and distributing bulk Active Pharmaceutical Ingredients throughout France and Europe, in cooperation with the best International and fully compliant manufacturers for Human, Animal Health and Nutritional Industries.

Our basic philosophy has always been to develop a successful long term partnership between our Manufacturers and Clients.

Our knowledge and our capacity to adapt quickly to the changing expectations of the market mean that we are proud to count the World’s leading pharmaceutical companies amongst our customers.

With HEPARTEX you benefit from:

— The flexibility of an independent and strongly client-oriented structure.

— Technical and commercial expertise: our highly committed and experienced team is made up exclusively of chemists and pharmacists, with more than 25 years experience in the International market.

— A unique HEPARTEX / VENIPHARM offer, based on our ability to provide a global service focusing on individual requirements:

— Supply of active ingredients    — Registration dossiers    — Marketing Authorisations    — Access to finished dosage forms

Expertise & competence

A guarantee of efficient and tailored services to contribute to the success of our partners:

Hepartex is a marketing and distribution company operating as the link between the API producers and the pharmaceutical industry. Hepartex offers a tailor-made service, totally transparent with respect to both pharmaceutical companies and suppliers, whilst guaranteeing absolute confidentiality.

Marketing & Distribution Services:

— Identify the projects and business opportunities, by maintaining our close and regular contacts with our clients from R&D to logistic departments.
— Anticipate the changing market conditions and customer demands.
— Supply and distribute APIs from manufacturers to end users through a reliable, efficient and flexible supply chain: order — delivery — invoicing (in accordance with GDP regulation).

Technical & Regulatory Services:

— Evaluate patents together with external experts.
— Provide a close and continuous scientific monitoring between our manufacturers and our clients at all stages of product life cycle.
— Assist and advise our partners in compiling and filing technical documentation. (EDMF, COS….).

Custom Synthesis & Outsourcing:

— Select manufacturers able to develop custom-made synthesis for products not available on the market. (Provision of quantities from kilo and pilot scale to cGMP production)
— Research specific products through our large worldwide network of suitable producers to find the most appropriate match to the requirements of the pharmaceutical companies.
— Strive to achieve strong, long term International partnerships with major world producers: development of new products in liaison with R&D departments, technological and commercial monitoring.


Source: Hepartex

[Read more!]

Seppic — Company Profile

SEPPIC SA Tour Kupka C 7, boulevard Franck Kupka 92039 Paris - La Défense Cedex France Tel.: +33 (0)1 55 91 57 00 Fax: +33 (0)1 55 91 50 50 Email: info.seppic@airliquide.com Website: http://www.seppic.com/

SEPPIC currently has over 600 staff world-wide. Together, they are creating, developing and promoting innovative speciality chemical and biological products designed to meet the requirements of a wide range of markets including cosmetics, human health, animal health, nutrition, textiles, paper, fertilisers, lubricants, drilling, detergents, optical cables, glass, building, resins, plastics and polymers, paints and inks. SEPPIC offers its customers a wide range of high performance and innovative products.

SEPPIC is a company based within the international Air Liquide group. The state of the art ressources of Air Liquide allow SEPPIC to create the products needed in tomorrow's markets.

SEPPIC has widely recognised international expertise dedicated to ensuring customer satisfaction offering made-to-measure services, with the aim of Total Quality, to meet the economic challenges of the 21st century.

R&D, Marketing

Research lies at the heart of our company. We have brought our Research, Development and Marketing departments together so that our research and development is in touch with market trends.

This enables us to offer tools and services able to meet rapidly changing requirements.

Control over the design, the application and the use of our speciality chemical and biological products are essential for developing our markets.

The Castres Research Centre places its science and services at the service of customers to develop products for the future.

Over 80 research workers apply their expertise to synthesising chemical and biological products and improving the performance of our speciality chemicals, in particular for the beauty, medicine, health and hygiene markets as well as special applications for glass, lubricants, plastics and polymers, paper and textiles.

SEPPIC's research is also based on collaboration with public and private research organisations such as CNRS, INRA, INSERM and AFSSA. These joint research projects enable SEPPIC to respond more accurately and more quickly to meet the market requirements for technical performances.

Quality

The quality of products and services, environment, health and safety issues have been central to SEPPIC's strategy since 1989.

Its Total Quality objective is based on continual staff training and staff motivation and has clearly defined aims: respect for its customers, the environment and its staff and compliance with regulations.

Quality: always aiming to improve customer satisfaction while listening to them.

SEPPIC is certified to ISO 9001 to ensure control over all aspects from safety to use of its products. The "processus" management according to V 2000 is underway.

— Quality policy and specific improvement objectives
— Co-operation with suppliers, sub contractors and customers
— Improving the reliability of processes and production equipment
— Continual improvement of manufacturing practices

Health and Safety: objective "zero accidents"

— Procedures, audits, objectives and annual reports
— Motivation, training and preventive education
— Daily safety training
— Control over products used and the risks they represent
— Appropriate work methods and means of protection

Environment: protection of our natural environment

The environment is of major concern to SEPPIC:

— ISO 14001 certification mid 2000
— Control and reduction of liquid waste and pollutant gases
— Studies of waste and waste treatment
— Studies of risks and prevention of technological risks
— Product life cycle environmental accounting

Improvement of good manufacturing and responsible care practises is a permanent concern.


Other locations in France:

SEPPIC has two production subsidiaries in France and a new subsidiary in Antwerp, Belgium.
Each has its own range of speciality chemicals with production management systems controlling quality, productivity and total traceability.
As part of the Total Quality policy, Good Manufacturing Procedures are gradually being introduced in the various units.

SEPIPROD Castres
127, chemin de la Poudrerie
81108 Castres
France
Tel.: +33 (0)5 63 72 69 69
Fax: +33 (0)5 63 72 69 70

This unit covers an area of 8 hectares and manufactures 600 different products with an annual output of 30,000 tonnes. Castres produces mainly surfactants and surfactant-based products (sorbitan esters, alkylpolyglucosides, amides, betaines, etc.).

Additional products include, for example, polymers, pharmaceutical and veterinary excipients as well as glass frosting materials and special products for optical fibre cables.


Givaudan-Lavirotte
56, rue Paul Cazeneuve
BP 8344
Lyon 08
France
Tel.: +33 (0)4 78 61 55 00
Fax: +33 (0)4 78 61 55 94

The Givaudan-Lavirotte unit makes pharmaceutical and nutritional products and also provides services to the cosmetics industry. Its products are mainly used as ingredients for health products (mineral salts, nicotinates and undecylenates, protein surfactant complexes, etc.).


Source: Seppic

[Read more!]

Isochem — Company Profile

Isochem SA 12, quai Henri IV 75194 Paris Cedex 04 France Tel.: +33 (0)1 49 96 72 00 Fax: +33 (0)1 49 96 73 00 Website: http://www.isochem.fr/

ISOCHEM is a technology driven organization dedicated to the development of processes and the production of fine chemicals.

ISOCHEM offers its customers both a service of custom manufacturing, seamless throughout the life of their projects, and a catalogue of products derived from its core technologies and background.

ISOCHEM supplies its customers with high quality products and services in total compliance with the regulatory requirements and with a continuous focus on safety and sustainability.

ISOCHEM bases its growth on the value of its teams and trustful relations with all partners.

Profile

ISOCHEM offers exclusive or non exclusive product listings stemming from its basic technologies.

Boasting industrial scale expertise in multi-steps chemical synthesis processes, most of which bringing organic chemical reactions into play, ISOCHEM offers its customers its renowned skills in two specific fields: safe implementation of hazardous goods such as phosgene or hydrazines and particularly delicate aminoacids and peptide chemistry.

From process design to industrial operations, the whole service is ISO 9001 certified and complies with the most stringent quality standards in each field concerned.

The pharmaceutical-dedicated production sites are cGMP approved and undergo frequent audits by the American Food and Drug Administration.

Markets

For more than 30 years of partnership with the life sciences and speciality chemicals industries, ISOCHEM has developed a broad experience in the management of complex multistep synthesis from kilo laboratory to commercial scale production.
More over, ISOCHEM contributes to enhancing our quality of life, in a wide range of applications in the following markets:

Pharmaceutical:
ISOCHEM provides high quality services and products to pharmaceutical companies under cGMP or non cGMP requirements:
— Exclusive custom synthesis and development
— Generic Active Pharmaceutical Ingredients
— Pharmaceutical intermediates and active ingredients
— Excipient
— Aminoacid derivatives and Peptides

Cosmetics:
ISOCHEM supplies solutions and products to enhance your cosmetic project.
— Exclusive custom synthesis and development

Plant protection:
ISOCHEM has a long history relating to the development, scaling up, manufacture of molecules used in the Plant Protection sector. We are serving the major agrochemicals companies as well as smaller niche agrochemicals actors in the following segments:
— Exclusive custom synthesis and development
— Insecticides
— Fungicides
— Herbicides
— Plant growth regulators
— Biocides chemicals

Speciality intermediates:
ISOCHEM offers various chemicals for the Speciality Intermediates segments, these chemicals are using a wide range of technologies and industrial production scales.
— Exclusive custom synthesis and development
— Polymer chemical: ISOCHEM is offering intermediate used in the manufacture of organic peroxides, cross linking agent and monomer, polymer additives for polymer industry.
— Electronics: Production of Lithium battery electrolytes for mobil phones as well as various intermediates used in the liquid crystal, photoresists and LCD industries.

ISOCHEM is offering a range of scratch resistant varnishes with various applications from the protection of military aircraft windows, ski goggles to ophthalmic glasses.
— Paper Industry: ISOCHEM offers coating chemicals enhancing specific properties required by the customer.
— Imaging chemicals: Supply of molecules used in the manufacture of photographic, reprographic chemicals and thermal paper.


Source: Isochem

[Read more!]

Axyntis — Company Profile

Axyntis Group Bioparc 8, rue de la Croix Jarry 75013 Paris France Tel.: +33 (0)1 44 06 77 00 Fax: +33 (0)1 44 06 76 99 Email: contact@axyntis.com Website: http://www.axyntis.com/

Leading fine and specialty chemicals company, French-based, Axyntis independent group with its 350 employees offers a deep rooted technical experience — the history of dyes activity started in 1881 at Saint-Marcel and the history of fine chemicals in 1879 at Grasse under the name "Schmoller et Bompard" for perfumery. This group designs innovative chemical processes and offers project management in close relationship with its customers.

Axyntis group has two divisions. One is dedicated to dyes: Steiner. One is dedicated to fine chemicals: Axyntis fine chemicals. Each division has its specificity even if they share the same safety and environment policy as well as common services to develop synergies.

The dyes division, Steiner, is a synthetic dye producer since 1881. Dyes are formulated for petroleum, oils, paper, cardboard, leather, textile, wood, ink, plus various other applications. 80 people are working for Steiner in France, St Marcel, and produce 8000 tons of formulated products per year. Steiner R&D Laboratory — 10 people — formulates and develops new technologies for the future of our customers. Steiner customers are located in Europe, America, Africa, and in the entire Mediterranean Basin. Concerned by environment protection, Steiner is equipped with a water treatment station. Steiner is certified ISO 9001 and ISO 14001.

Steiner has also a branch based in UK under the name of Steiner UK which operates for customers locally and brings an internal second source to secure the supply chain of its European customers.

The fine chemicals division, Axyntis fine chemicals, along with capacity of 380 m³ under cGMP, is split in four different plants, each of them having its own specificity:

These plants are complementary and enable a safety supply chain solution to the customers including internal back up strategy:

• Orgapharm is designed for key advanced intermediates and APIs for Pharmaceuticals industry and LCD under exclusive relationship;
• Centipharm is designed for exclusive key intermediates and generic API with its own regulatory support (US and European DMF and CEP);
• All’Chem is designed for key intermediates for electronic, agro and specialty;
• Synthexim is designed for key intermediates for pharma chemicals.

Both Orgapharm and Centipharm bring in addition Ramp;&D centers and Pilot capabilities which make these two plants a "one stop shop" for customers with a unique place for efficient transition phase between R&D and production (process development; scale up).

The four plants are Seveso II and two of them are high level compliant: this reflects the ability to perform complex chemistry and specific reactions that require high level of technical competence and specialized know-how.

With a competitive cost structure and a business network extended recently in the US and Asia, Axyntis group offers the best balance between expertise in specific reactions, flexibility, cost efficiency and time management for projects of innovative and fast growing companies in Europe, North America and Asia.

Orgapharm Rue du Moulin de la Canne 45300 Pithiviers France Tel.: +33 (0)2 38 06 20 00 Fax: +33 (0)2 38 30 24 24 Plant Director: Emmanuel Huet (emmanuel.huet@axyntis.com) A polyvalent plant with high level cGMP compliance in both intermediate and API productions.

Centipharm Chemin de la Madeleine BP 45249 06131 Grasse Cedex France Tel.: +33 (0)4 93 70 01 32 Fax: +33 (0)4 93 70 05 65 Works manager: Guy Duquesne (guy.duquesne@axyntis.com) Fine organic chemical products with both high added value and high level GMP compliance.

All'Chem Rue Marceau BP 577 03108 Montluçon France Tel.: +33 (0)4 70 03 75 25 Fax: +33 (0)4 70 03 08 79 Plant Director: Pascal Feniet (pascal.feniet@axyntis.com) For high production volumes and long-lasting production campaigns of chemical specialties.

Synthexim Rue des Mouettes ZI des Dunes 62100 Calais France Tel.: +33 (0)3 21 96 85 00 Fax: +33 (0)3 21 96 04 25 Plant Director: Bertrand Cazin (bertrand.cazin@axyntis.com) A 24/7 production plant operating in a five shifts system to supply your fine organic chemicals.

Steiner SAS 9, route de Rouen 27950 Saint-Marcel France Tel.: +33 (0)2 32 64 58 40 Fax: +33 (0)2 32 64 58 49 Plant Director: Laurent Choumery (laurent.choumery@axyntis.com) Our industrial mastering: a response to all your colouring needs.

Source: Axyntis

[Read more!]

PCAS Biosolution — Company Profile

PCAS Biosolution SAS 70, allée Graham Bell Parc Georges Besse 30000 Nîmes France Tel.: +33 (0)4 66 27 29 21 Fax: +33 (0)4 66 27 29 20 Email:info@pcas-bio.com Website: http://www.pcas-bio.com/

PCAS Biosolution is a joint-venture created in 2006 by PCAS and Protéus with headquarters in Longjumeau, France and operating facilities located in the South of France. PCAS Biosolution aims at providing our customers all the value drivers of integrating biocatalysis into chemical processes.

Headquarters
23, rue Bossuet
Z.I. de la Vigne Aux Loups
91160 Longjumeau
France


Vision & Strategy

PCAS Biosolution integrates chemistry and biotechnology to provide a unique and exclusive offering to the pharmaceutical industry.

The Company combines and integrates multidisciplinary expertise, proprietary technologies and multi-scale production capabilities in both chemistry and biotechnology. We focus on the synthesis of APIs, intermediates and building blocks using chemo-biocatalytic manufacturing routes. Biocatalytic steps provide scalability, versatility and a high chemo-, regio-, stereo- and enantioselectivity.

Benefits include the ability to produce complex intermediates and APIs using scalable routes, reduce manufacturing costs, improve productivity, reduce byproducts and develop competitive green chemistry process.

We are committed to be your quality partner for the development, manufacture and long term supply of your intermediates and APIs using the optimal chemo-biocatalytic routes that meet your specifications of quantity, time, quality and targeted price.

Mission

Our mission is to provide significant value to drug developers by designing, developing and implementing new cost-effective and scaleable manufacturing routes to APIs and intermediates which combine both chemistry and biotechnology. The company aims at creating brand new routes to innovative products or at improving the manufacturing process of currently marketed products. Our focus is on reducing the number of manufacturing steps, decreasing by-products, avoiding hazardous chemicals, using lower cost raw material, enhancing purity and process enantio-selectivity, increasing conversion rate and improving overall yield, energy consumption and performance.

More value also means more Industrial Property: biocatalysts and processes developed are generally proprietary, thus providing opportunities to the drug developers to reinforce and extend the lifetime of their existing intellectual property.

With PCAS Biosolution, your projects will benefit from a unique, comprehensive and integrated chemo-biocatalytic R&D, industrial and regulatory platform.


Source: PCAS Biosolution

[Read more!]

PCAS — Company Profile

PCAS BP 181 23, rue Bossuet Z.I. La Vigne aux Loups 91160 Longjumeau France Tel.: +33 (0)1 69 09 77 85 Fax: +33 (0)1 69 74 81 04 Email:infopharma@pcas.fr Website: http://www.pcas.fr/

PCAS is the special partner of pharmaceutical laboratories for the development, production and market launch of bulk APIs.

PLANTS:

Usine de Bourgoin
15, avenue des frères-Lumière
38300 Bourgoin-Jallieu
France
Tel.: +33 (0)4 74 93 63 33
Fax: +33 (0)4 74 28 29 98

Usine de Couterne
Route de Lassay
61410 Couterne
France
Tel.: +33 (0)2 33 37 50 20
Fax: +33 (0)2 33 37 50 21

Usine de Limay
19, route de Meulan
78520 Limay
France Tel.: +33 (0)1 34 78 87 87
Fax: +33 (0)1 30 92 03 46


EXPANSIA

Headquarters
BP 181
23, rue Bossuet
ZI de la Vigne-aux-Loups
91160 Longjumeau
France
Tel.: +33 (0)1 69 09 77 85
Fax: +33 (0)1 64 48 23 19

Plant
Route d’Avignon
30390 Aramon
France
Tel.: +33 (0)4 66 57 01 01
Fax: +33 (0)4 66 57 01 48


SOCIÉTÉ BÉARNAISE DE SYNTHÈSE

Headquarters
BP 181
23, rue Bossuet
ZI de la Vigne-aux-Loups
91160 Longjumeau
France
Tel.: +33 (0)1 69 09 77 85
Fax: +33 (0)1 64 48 23 19

Plant
Plateforme Sobegi
Pôle 4
Avenue du Lac /R.D.281
64150 Mourenx
France
Tel.: +33 (0)5 59 92 75 33
Fax: +33 (0)5 59 92 75 31


VLG CHEM

Headquarters
BP 181
23, rue Bossuet
ZI de la Vigne-aux-Loups
91160 Longjumeau
France
Tel.: +33 (0)1 69 09 77 85
Fax: +33 (0)1 64 48 23 19

Plant
35, avenue Jean-Jaurès
92390 Villeneuve-La-Garenne
France
Tel.: +33 (0)1 46 85 91 91
Fax: +33 (0)1 46 85 91 61


PROTEUS

Headquarters
70, allée Graham Bell
Parc Georges Besse
30000 Nîmes
Tel.: +33 (0)4 66 70 64 64
Fax: +33 (0)4 66 70 64 60
www.proteus.fr


Source: PCAS

[Read more!]

Ipsen — Company Profile

SCRAS IHB Research and Development Z.I. de Courtaboeuf 5, avenue du Canada 91966 Les Ulis Cedex France Tel.: +33 (0)1 60 92 20 00 Fax: +33 (0)1 69 07 38 02 Website: http://www.ipsen.com/

Ipsen is an innovation driven international specialty pharmaceutical group, which currently markets more than 20 drugs, employing nearly 4,000 people around the world.

Its development strategy is based on a complementary combination of specialised products, which are growth drivers, in the Group’s targeted therapeutic areas (oncology, endocrinology and neuromuscular disorders) and primary care products, which help finance its Research and development activities. The location of its four Research and Development centres (Paris, Boston, Barcelona, London) and its peptide and protein engineering platform give the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. More than 700 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. This strategy is also supported by an active partnership policy.

Ipsen has industrial sites in France, the United Kingdom, Ireland, Switzerland, China and the United States, and plantations and leaf-drying facilities in France, China and the United States. Each of the Group’s manufacturing facilities focuses on a particular technology to maximise its operational efficiency. For instance, the Dublin site (Ireland) is devoted to the purification and formulation of proteins, while the Dreux plant (France) specialises in the manufacturing and packaging of high volumes of oral formulations.

Furthermore, Ipsen promotes continuous productivity improvement of its manufacturing processes. Upstream efforts by manufacturing, development and research teams promote mutual enhancement. This integration is a necessary step towards improving product quality, guaranteeing patient safety and developing optimal manufacturing processes within the Group’s cost optimisation rationale.

Products

In both its targeted therapeutic areas and in primary care, Ipsen has a diversified portfolio of leading medicines that have demonstrated a good safety profile.

The Group's product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology and neuromuscular disorders), which are its primary areas of development. The Group also markets products in other therapeutic areas in which it boasts longstanding expertise (gastroenterology, cardiovascular and cognitive disorders). To a great extent, these are composed of primary care.

Targeted therapeutic areas
Oncology: Decapeptyl®
Endocrinology: Somatuline®, NutropinAq®, Increlex®
Neuromuscular disorders: Dysport®

Primary care
Gastroenterology: Smecta®, Forlax®
Cognitive disorders: Tanakan®
Cardiovascular: Ginkor Fort®, Nisis® & Nisisco®


Contact information:

France — Manufacturing and Supply Organisation
SCA Saint Jean d'Illac
Chemin du Blayais
33127 Saint Jean d'Illac
France
Tel: +33 (0)5 56 21 67 75
Fax: +33 (0)5 56 21 87 00

France — Manufacturing and Supply Organisation
SCA Saint Jean d'Illac
Plantation Captieux - Les cultures
33840 Captieux
France
Tel: +33 (0)5 56 65 68 34
Fax: +33 (0)5 56 65 68 57

France — Manufacturing and Supply Organisation
Beaufour Ipsen Industries SAS
rue d'Ethe Virton
28100 Dreux
France
Tel: +33 (0)2 37 65 46 00
Fax: +33 (0)2 37 46 85 98

France — Manufacturing and Supply Organisation
Beaufour Ipsen Industries SAS
Saint Véran — Chemin de Reydet
84800 L'Isle-sur-la-Sorgue
France
Tel: +33 (0)4 90 21 27 00
Fax: +33 (0)4 90 38 20 65

France — Manufacturing and Supply Organisation
Ipsen Pharma Biotech SAS
Z.E. de Signes — CD 402
83870 Signes
France
Tel: +33 (0)4 94 10 76 76
Fax: +33 (0)4 94 10 76 79

France — International Operations
Beaufour Ipsen Pharma
37, rue Spontini
75116 Paris
France
Tel: +33 (0)1 53 65 76 00
Fax: +33 (0)1 47 55 84 44

France — France Operations
Beaufour Ipsen Pharma
24 rue Erlanger
75016 Paris
France
Tel: +33 (0)1 44 96 13 13
Fax: +33 (0)1 44 96 11 99

France — Ipsen Corporate Headquarters
Ipsen
42, rue du Dr Blanche
75016 Paris
France
Tel: +33 (0)1 44 30 43 43
Fax: +33 (0)1 44 30 43 21

France — Research and Development
SCRAS IHB
Z.I. de Courtaboeuf
5, avenue du Canada
91966 Les Ulis cedex
France
Tel: +33 (0)1 60 92 20 00
Fax: +33 (0)1 69 07 38 02

Source: Ipsen


History
The Ipsen story began when Laboratoires Beaufour was founded in 1929 by Dr. Henri Beaufour. In 1969 the Institut Henri Beaufour research centre was founded. In 1975, IPSEN was created (Institut de Produits de Synthese et d'Extraction Naturelle). Ipsen (Greece) was formed in 1980, and Ipsen International was created in 1981 in London to coordinate clinical and regulatory affairs, followed by Ipsen in Belgium in 1982. Fondation Ipsen was founded in France in 1983. In 1986, Laboratoires Astier was acquired and Ipsen Biotech was formed, and in 1987 the first Asian office was opened. 1986 saw the acquisition of LASA Laboratories in Spain (now called Ipsen Pharma), and expansion into the USA. In 1994, Speywood was acquired in the UK (now named Ipsen). In 2003, Beaufour Ipsen changed its name to Ipsen.

Ipsen's strategy relies on three factors: operational excellence in selected therapeutic areas, a policy of active alliances both in R&D and operations, and an effort to expand the international scope of the business. Ipsen carries out R&D, Formulation and Production, and Marketing. Ipsen is the fifth largest French pharmaceutical company. Ipsen operates from four R&D sites: Biotechnology in the USA (Boston), International Clinical Development, Business Development and Licensing in the UK (London), Formulation Research in Spain (Barcelona) and therapeutic agents of low molecular weight in France (Paris). The company's subsidiaries are located in Europe, the USA, and Asia/Australia. In the rest of the world, Ipsen operates through commercial partnerships.

Source: Pharmalicensing

[Read more!]